Will Nano Dimension’s new leadership choose Infinite Epigenetics, Tang Capital or a third path?

Nano Dimension Ltd. (Nasdaq: NNDM) appointed Moshe Rozenbaum as interim chief executive officer and Phillip Borenstein as board chair on July 21, 2026, one day after a settlement with Murchinson Ltd. reconstituted the board. Rozenbaum succeeds David Stehlin, who resigned from the board and every other Nano Dimension position alongside three fellow directors under the agreement. The appointments place a former Nano Dimension corporate development executive at the centre of decisions involving a $441.6 million reported liquidity base, pending asset sales and an unfinished strategic alternatives process. The new leadership must now decide whether to preserve the proposed $890 million Infinite Epigenetics combination, engage with Tang Capital Management’s $1.60-per-share cash proposal or choose another direction. The central tension is clear: Nano Dimension is promising operating continuity while its strategic future may be rewritten.

Why does Nano Dimension’s interim CEO appointment represent more than a routine succession?

The chief executive change is the second stage of a broader governance reset rather than an isolated personnel decision. Nano Dimension and Murchinson announced on July 20 that they had settled their proxy contest under an agreement executed on July 17. The settlement cancelled the extraordinary general meeting scheduled for July 31 and resulted in Robert Pons, Joshua Rosensweig, Andrew Sriubas and David Stehlin leaving the board.

Three directors nominated by Murchinson, Paul Fruchthandler, Moshe Rozenbaum and Eliezer Tarlow, joined the board. Phillip Borenstein, who had served as a director since December 2025, remained and was subsequently elevated to chair. The resulting structure gives Nano Dimension a four-member board in which three directors entered through the Murchinson settlement.

Rozenbaum’s elevation to interim chief executive therefore joins boardroom change with executive authority. His immediate mandate is continuity, but the board’s reference to evaluating strategic priorities indicates that continuity should not be interpreted as automatic continuation of every initiative inherited from the previous leadership.

That distinction matters because Nano Dimension is no longer pursuing a conventional expansion plan within additive manufacturing. It has been selling product lines, reducing fixed costs and considering transactions that could redirect its capital and Nasdaq listing into a substantially different industry. The interim chief executive is consequently overseeing a corporate transition, not merely filling an empty office.

How could Moshe Rozenbaum’s capital-markets background shape Nano Dimension’s next strategic decision?

Rozenbaum previously served as Nano Dimension’s vice-president of corporate development, leading strategic initiatives and investor engagement. He has also served as chief financial officer and chief operating officer of Fluent Trade Technologies, led business development at Yedid Capital Management and currently chairs the audit committee of Nasdaq-listed Lifeward Ltd.

That background appears relevant to Nano Dimension’s immediate needs. The company requires someone capable of comparing transaction structures, assessing cash deployment, communicating with shareholders and preserving financial controls while the board examines competing strategic paths. Rozenbaum already knows the company and its shareholder base, reducing some of the disruption normally associated with an external interim appointment.

The open question is whether Nano Dimension needs a capital-markets specialist for a defined transaction period or an operating executive capable of rebuilding a durable commercial business. The board has not disclosed a timetable for appointing a permanent chief executive, and the interim designation preserves flexibility while strategic alternatives are reassessed.

Rozenbaum’s appointment may accelerate decision-making because he combines internal knowledge with experience in corporate development. It does not, by itself, resolve the quality or valuation of the options before the company. His first meaningful test will be whether Nano Dimension can explain its chosen direction with clearer economics than investors received during the preceding proxy contest.

What does the Murchinson settlement change about governance and accountability at Nano Dimension?

The settlement ends the immediate expense and uncertainty associated with the July 31 shareholder meeting, but it also shifts responsibility for the company’s strategic outcome. The newly constituted board can no longer attribute delays or unclear priorities to a continuing contest for board seats. It now owns the capital-allocation decisions that follow.

Although three directors were nominated by Murchinson, their legal responsibilities are owed to Nano Dimension and its shareholders as a whole. The settlement should therefore not be treated as proof that every prior Murchinson position will become company policy. The directors must independently assess the Infinite Epigenetics proposal, Tang Capital Management’s approach, pending disposals and the value of continuing Nano Dimension’s remaining operations.

A smaller board may allow decisions to move faster, particularly after months of public disagreement. However, the loss of four directors and the chief executive in a single settlement also reduces institutional continuity at a time when Nano Dimension is handling several complex transactions.

Phillip Borenstein’s role could become important in balancing those pressures. His experience at Hamilton Equity Partners includes mergers, acquisitions and portfolio management, giving the chair relevant transaction expertise. Investors will nevertheless judge the board on disclosure quality, decision discipline and measurable value creation rather than biographies.

Will Nano Dimension’s new board preserve the proposed $890 million Infinite Epigenetics combination?

Nano Dimension signed a non-binding term sheet with Infinite Epigenetics on June 15 after reviewing approximately 20 strategic opportunities. The proposed combination valued Infinite Epigenetics at $890 million and would have shifted Nano Dimension from industrial digital manufacturing towards artificial intelligence-powered preventive health and molecular diagnostics.

Under the contemplated structure, Nano Dimension or a successor public company would acquire all of Infinite Epigenetics. Existing Nano Dimension shareholders were expected to retain a meaningful minority interest based on a stated value for their shares representing a 20% premium to estimated net cash at closing. The combined company was expected to hold more than $400 million in cash and trade under the proposed IEAI ticker.

Nano Dimension shareholders were also expected to receive contingent value rights linked to proceeds from certain legacy asset disposals. Those rights were conditional and could not be treated as guaranteed additional value. The term sheet remained subject to due diligence, final negotiations, board approval, shareholder approval and applicable regulatory requirements.

The original term sheet included a 30-day exclusivity period. That period had elapsed before the leadership announcement, and Nano Dimension had not disclosed a definitive merger agreement by July 21. The absence of a final agreement does not establish that the proposed combination has been abandoned, but it leaves its current status unresolved.

The new board must now decide whether the proposed healthcare pivot offers a better risk-adjusted return than distributing capital, pursuing a cash sale, completing the disposal programme or identifying another operating platform. If it keeps the Infinite Epigenetics plan, investors will require updated ownership percentages, financial projections, capital requirements, governance terms and independent support for the proposed valuation.

How should Nano Dimension weigh Tang Capital’s $1.60 cash proposal against strategic optionality?

Tang Capital Management disclosed a 6.8% Nano Dimension stake on June 30 and submitted a non-binding proposal under which an affiliate would acquire Nano Dimension for $1.60 per share in cash. Tang Capital Management stated that it had funding available, but the proposal remained subject to confirmatory diligence and negotiation of definitive documents.

At Nano Dimension’s July 21 closing price of $1.49, the proposed consideration represented an approximately 7.4% premium to the market price, while the shares traded about 6.9% below the proposed offer value. That spread indicates some market caution over whether the proposal will progress, whether its terms will change or whether the board will select an alternative.

The cash offer provides a relatively simple benchmark because it assigns an explicit near-term value to the shares. The Infinite Epigenetics proposal offers a more complex combination of minority ownership, exposure to a healthcare artificial intelligence platform and contingent proceeds from legacy assets. Its potential upside could be larger, but shareholders would also assume valuation, execution, regulatory and commercial risks that do not accompany an all-cash exit to the same degree.

The new board should not automatically accept the highest visible number or preserve the most ambitious narrative. Its task is to compare the certainty, timing, conditionality and expected value of each alternative. A credible explanation of that comparison would do more for investor confidence than another broadly worded commitment to maximising shareholder value.

Why does Nano Dimension’s $441.6 million liquidity position intensify capital-allocation pressure?

Nano Dimension reported $441.6 million in cash, cash equivalents, deposits, restricted deposits and marketable equity securities at March 31, 2026. First-quarter revenue increased 106% to $29.7 million, partly reflecting the consolidation of MarkForged, but the company still recorded a $12.5 million adjusted EBITDA loss and a $69.7 million net loss that included $40.4 million of impairment charges. Nano Dimension first-quarter results

For 2025, revenue rose 77.3% to $102.4 million, while the adjusted EBITDA loss narrowed to $53.2 million. The net loss from continuing operations remained substantial at $100.4 million. Nano Dimension subsequently suspended its 2026 guidance because product disposals and strategic alternatives made the earlier outlook less meaningful.

The March liquidity figure was approximately $132 million above Nano Dimension’s latest market capitalisation of roughly $309 million on a headline basis. That comparison helps explain activist interest, but it is not equivalent to saying shareholders could receive the full difference. Reported liquidity includes restricted deposits and marketable securities, while operating losses, transaction expenses, contractual commitments and working-capital needs continue to consume resources.

Cash-rich companies can sometimes appear straightforward until the board must decide what the cash is actually for. Nano Dimension’s valuation suggests investors are applying a material discount for continued losses, uncertain transaction outcomes and doubts over how much of the capital base will ultimately reach shareholders or generate acceptable returns.

What must Nano Dimension protect operationally while the reshaped board reviews its future?

Nano Dimension has completed the sale of its additively manufactured electronics and discontinued Fabrica product lines to Inspira Technologies OXY B.H.N. Ltd. for $2 million upfront and up to $10.5 million of performance-based deferred consideration. Management expected the transaction to reduce annualised cash burn by approximately $10 million.

The company also agreed to sell MarkForged, Inc. to Stratasys Ltd. for $42.5 million in cash. That transaction remains expected to close during the second half of 2026, subject to customary conditions and regulatory approvals. Nano Dimension intends to retain the Markforged Metal Binder Jetting product line, while the wider sale is expected to reduce annualised cash burn by approximately $15 million.

On July 17, Nano Dimension also agreed to terminate its Waltham headquarters lease at the end of 2026. The company expects to pay approximately $13 million to eliminate about $38 million of future lease costs, producing estimated cumulative net savings of roughly $25 million through 2031.

These initiatives were negotiated before the board settlement, but the new leadership inherits responsibility for completing them. Customer service, employee retention, regulatory approvals and transaction execution cannot be allowed to deteriorate while the board considers a larger strategic pivot. A strategy review can create value only if the assets being reviewed remain commercially and operationally intact.

What does NNDM’s latest stock performance reveal about sentiment after the leadership reset?

Nano Dimension shares closed at $1.49 on July 21, down 2.6% for the session. The stock gained approximately 0.7% over five days and 8.8% over one month, while remaining within a 52-week range of $1.19 to $2.32. The July 21 chief executive announcement arrived after the regular session, meaning the closing decline cannot reasonably be attributed to the appointment.

After-hours trading lifted the shares to approximately $1.51, a gain of about 1.3%, but the move involved only around 37,000 shares. That is too little volume to establish a durable verdict from investors. The July 20 session, when the Murchinson settlement became public, generated considerably higher volume of approximately 13.9 million shares.

The broader pattern suggests event-driven interest rather than a confirmed operating rerating. NNDM remains well below its 52-week high, and the market capitalisation continues to sit below the company’s reported liquidity base. Investors appear to recognise the value of the balance sheet while applying a significant discount for cash burn, strategic uncertainty and execution risk.

Which milestones will show whether Nano Dimension’s board reset is creating shareholder value?

The first proof point will be a formal update on the strategic alternatives review. The board needs to clarify whether discussions with Infinite Epigenetics remain active, whether Tang Capital Management’s proposal is being evaluated and whether other alternatives have entered the process.

The second test will be financial execution. Completion of the MarkForged sale, delivery of the promised cost reductions and evidence that quarterly cash consumption is falling would strengthen the company’s negotiating position. Further impairments, disposal delays or rising professional expenses would weaken it.

The third milestone concerns leadership permanence. Rozenbaum may remain appropriate if Nano Dimension’s immediate objective is to complete a transaction or capital restructuring. A continuing standalone business, particularly one expected to enter a new industry, may require a different long-term operating profile.

Nano Dimension has gained the ability to move beyond its proxy contest, but the settlement has not created value by itself. The board reset will become economically meaningful only when the new leadership converts financial flexibility into a clearly valued transaction, a sustainable operating model or a demonstrably more efficient return of capital.

Key takeaways on Nano Dimension’s leadership reset, strategic review and NNDM valuation

• Nano Dimension appointed Moshe Rozenbaum interim chief executive officer and Phillip Borenstein chair immediately after its settlement with Murchinson.
• The settlement cancelled the July 31 extraordinary general meeting and replaced four directors with three Murchinson-nominated directors.
• Rozenbaum’s background in corporate development, finance and investor engagement is relevant to Nano Dimension’s transaction-heavy strategic review.
• The proposed $890 million Infinite Epigenetics combination remained non-binding, with no definitive agreement disclosed by July 21.
• Tang Capital Management’s $1.60-per-share cash proposal provides a visible valuation benchmark but also remains preliminary and conditional.
• Nano Dimension reported $441.6 million of liquidity at March 31, exceeding its latest market capitalisation on a headline basis but not representing distributable net cash.
• Continued adjusted EBITDA losses and substantial impairment charges explain why the market applies a discount to the reported liquidity position.
• Completion of the $42.5 million MarkForged sale and delivery of expected cash-burn reductions are immediate operational tests for the new leadership.
• The next strategic disclosure must clarify whether Nano Dimension will pursue healthcare artificial intelligence, accept a cash transaction or select another route.